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Abstract 
Introduction: The cutaneous vascular manifestations of systemic sclerosis (SSc) comprise Raynaud’s 
phenomenon, cutaneous ulceration, telangiectasia formation and critical digital ischaemia; each of 
which are associated with significant disease-related morbidity. Despite the availability of multiple 
classes of vasodilator therapy, many of which have been the subject of RCTs, a limited number of 
pharmacological interventions are currently approved for the management of cutaneous vascular 
manifestations of SSc.  
Areas covered: A major challenge has been demonstrating treatment efficacy with examples of 
promising therapies yielding contrasting results in controlled trial settings. Differences between 
consensus best-practice guidelines, evidence-based recommendations and marketing approvals in 
different jurisdictions has resulted in geographic variation in clinical practice concerning the 
management of cutaneous vascular manifestations of SSc. Difficulty demonstrating treatment 
efficacy risks waning industry engagement for drug development programmes in this field. This 
article highlights the key challenges in establishing treatment efficacy and barriers that must be 
overcome to support successful clinical trial programmes across the spectrum of cutaneous vascular 
manifestations of SSc. 
Expert Opinion: The paucity of approved treatments for cutaneous vascular manifestations of SSc 
relates as much to challenges in clinical trial design and the need for reliable clinical trial endpoints, 
as to lack of therapeutic options. 
 
Abstract word count: 200 words 
 
Key Words: Systemic sclerosis, Raynaud’s phenomenon, Outcome Measures, Clinical Trials, Digital 
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1.0 Introduction 
Systemic sclerosis (SSc) is a multisystem disease characterised by a complex interplay of 
autoimmunity, aberrant tissue remodelling and vasculopathy related to dysregulated tissue injury 
and repair. When considering cutaneous disease in SSc, attention typically focusses on excessive 
dermal collagen deposition that justifies the historical appellation “scleroderma”; despite skin 
thickening not being a universal feature, one that is often absent at diagnosis and not uncommonly 
confined to the digits where its impact can remain limited. Cutaneous vascular manifestations, 
however, are omnipresent and an important requisite to diagnosis and classification of early disease. 
The relevance of the cutaneous vascular manifestations are easily overlooked by clinicians and 
researchers pre-occupied by potentially life-threatening internal organ manifestations but their 
importance to patients and impact on daily living should not be under-estimated. Unsurprisingly, 
vasodilator treatments have formed the mainstay of therapeutic intervention but such approaches 
do not directly target the endothelial damage and obliterative vascular remodelling that produce the 
cutaneous vascular manifestations of SSc. Delivering and demonstrating treatment efficacy for 
cutaneous vascular manifestations of SSc has been challenging and carries a risk of waning industry 
engagement for clinical trials within this field.  
The present review shall consider the cutaenous microangiopathy of SSc and its contribution to the 
four major cutaneous vascular manifestations of SSc; Raynaud’s phenomenon (RP), cutaneous 
ulceration (which includes but is not restricted to digital ulcers [DU]), telangiectasia formation and 
critical digital ischaemia (CDI). Many valuable reviews and clinical practice guidelines have 
considered the evidence-base for intervention for these disease manifestations and this review shall 
not attempt to replicate such work. Instead, I shall focus on our existing methods for assessing 
cutaneous manifestations of SSc, challenges surrounding clinical trial design and, where applicable, 
what clinical trial data might teach us of the relative merits and limitations of past endeavours.  The 
review shall primarily focus on outcome measures included in the provisional core set of outcomes 
for SSc clinical trials and those currently accepted by regulatory bodies assessing labelling claims for 
marketing authorization [1]. The potential future role of emerging methods such as non-invasive 
microvascular imaging as endpoints in clinical trials of cutaneous vascular manifestations of SSc shall 
be discussed where applicable. This article highlights many of the key challenges in establishing 
treatment efficacy and the barriers that must be overcome to support successful clinical trial 
programmes across the spectrum of cutaneous vascular manifestations of SSc. Presently, I shall first 
consider the nature of cutaneous vasculopathy in SSc and its relevance to disease pathogenesis.  
2.0 Body 
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2.1 The nature of cutaneous vasculopathy in SSc 
Endothelial injury is an important initiating event in SSc and histological analysis in early disease 
reveals a peri-vascular cellular infiltrate in tissues long before the emergence of overt fibrosis [2]. 
The inter-relationship between vasculopathy and fibrosis formed the basis of the “Vascular 
Hypothesis” proposed by Campbell and LeRoy which remains central to current doctrine regarding 
SSc pathogenesis [3]. The exact temporal relationship between endothelial injury and emergence of 
clinical sequalae of SSc has not been fully elucidated but it is cutaneous vascular features such as RP 
and puffy fingers (caused in part by vascular leak) that typically herald the onset of SSc; with both 
clinical manifestations forming part of the clinical criteria (alongside ANA positivity) in the proposed 
classification of very early systemic sclerosis [4, 5]. The period between the onset of RP and other 
disease manifestations varies greatly according to disease subset (and autoantibody specificity) with 
a mean time of 6.5 years between RP-onset and the first non-RP symptom (a curious but commonly 
applied method for delineating SSc disease onset) in patients carrying the anti-centromere 
autoantibodies typically associated with limited cutaneous SSc (lcSSc) [6].  The episodic nature of RP 
(at least in the early stages of the disease) highlights the functional impact of early vascular injury 
but peripheral vascular compromise in SSc is compounded by a progressive structural obliterative 
microangiopathy; the effects of which can be directly visualised at the nailfold where morphological 
abnormalities can be used in the diagnosis and classification of early disease when skin thickening 
and other fibrotic complications of SSc may not be present [7, 8, 9] (Figure 1). The gradual evolution 
of nailfold capillary abnormalities (best observed over months and years) highlights the progressive 
nature of the cutaneous vasculopathy and is reflected in the terminology applied to the 
characteristic nailfold capillary changes associated with “early” (relatively few giant capillaries and 
microhaemorrhages with little or no capillary drop out) and “late” (more extensive capillary drop out 
and occasional large ramified bushy capillaries) disease [10]. Attention has relatively recently shifted 
from the diagnostic utility of nailfold capillaroscopy to its prognostic potential and there is growing 
evidence of an association between “late” nailfold capillary abnormalities and a broad range of 
clinical outcomes that, relevant to the scope of this review, include telangiectases [11], calcinosis 
[12], acro-osteolysis [13] and DU disease [14, 15, 16]. The progressive obliterative microangiopathy 
and capillary loss are thought to contribute to more pronounced and sustained cutaneous 
ischaemia. This could have important, but hitherto overlooked, implications for both current 
methods of assessment and potential efficacy of therapeutic intervention, as shall now be discussed.  
2.2 Raynaud’s phenomenon 
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RP occurs in virtually all patients with SSc and is consistently the highest ranked disease-specific 
manifestation of SSc in terms of frequency and impact [6, 17]. Whilst not life-threatening, SSc-RP is a 
major cause of disease-related morbidity in SSc and self-management is typically insufficient to 
control symptoms [18]. The term RP describes a symptom complex and is routinely used as an 
umbrella term to describe a heterogeneous group of disorders associated with varying degrees of 
functional and structural peripheral macro- and microvascular compromise, whose individual 
pathophysiologies differ markedly. The seemingly innocuous shared use of the term RP has had 
significant undesirable effects. Firstly, it has encouraged investigators to undertake mechanistic 
studies and clinical trials in mixed heterogeneous populations of patients [19, 20]. Secondly, it has 
resulted in a large number of reviews and clinical practice guidelines reporting on matters pertaining 
to the pathogenesis and management of “Raynaud’s” that insufficiently segregate the different 
causes of RP during the subsequent discourse. Finally, it has resulted in the same outcome measures 
being applied within different populations of patients despite the aforementioned marked 
differences in aetiopathogenesis.  
The 2-week Raynaud’s Condition Score (RCS) diary emerged in the mid-1990s for clinical trials of 
prostanoid therapy for SSc-RP [21, 22, 23]. The RCS diary allows patients to capture the frequency 
(weekly or daily number of attacks), duration and severity/impact of their Raynaud’s symptoms. 
Severity/impact of Raynaud’s is assessed using the RCS; a single-item 11-point numeric rating scale 
in which respondents are asked to consider up to 8 features of RP when considering their score; with 
the frequency and duration of attacks featuring prominently in the list. It is curious to note that the 
exact item wording of the RCS (and its predecessor the Raynaud’s Severity Scale) differ slightly in 
different studies which could have an important influence on RCS scores (Table 1).  Data from the 
original negative clinical trial of oral iloprost was used to validate the RCS diary [22, 24] although the 
approach taken was restricted by the clinical trial data available. For example, reliability assessments 
used pooled data from participants receiving active treatment, whereas responsiveness to change 
analysis used pooled data obtained from patients receiving placebo therapy [22, 24]. Moreover, 
whilst the RCS was shown to discriminate between patients with and without DU, the RCS item 
wording itself encouraged patients to consider painful sores when choosing their score (Table 1) [22, 
24]. Nonetheless, the RCS diary has subsequently been included in the provisional core set of 
outcome measures for SSc clinical trials and incorporated into the majority of SSc-RP clinical trials 
since its development [1]. In the UK, nifedipine (a calcium channel blocker) has been licensed by the 
Medicines and Healthcare Products Regulatory Agency as a treatment for RP since 1998. Since then, 
there have been a large number of clinical trials incorporating the RCS diary of vasodilator therapies 
including prostanoid therapies [22, 23], phosphodiesterase inhibitors [25, 26], nitrates [27], 
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endothelin receptor antagonists [28] and a non-prostanoid prostacyclin receptor agonist [29] in 
which treatment efficacy has been shown to be absent or modest at best. As a result, there are 
currently no EMA- or FDA-approved treatments for SSc-RP although treatments such as 
phosphodiesterase inhibitors, nitrates and prostanoid therapies have each been included in clinical 
guidelines on the management of SSc-RP [30, 31, 32]. Clinical trials incorporating the RCS diary (and 
other PRO instruments for assessing SSc-RP) have identified a high placebo response [33]. Recent 
work has also identified poor concordance with non-invasive vascular imaging approaches to 
assessing digital cutaneous perfusion [34, 35]. There is recognition within the SSc community that 
the RCS diary might be a barrier to drug development programs for SSc-RP [36]. Recent work has re-
appraised the patient experience of SSc-RP as groundwork for a novel patient-derived patient-
reported outcome (PRO) instruments for assessing SSc-RP. A large multicentre qualitative research 
study was undertaken that has identified a number of important patient experiences of SSc-RP that 
are not currently captured using existing PRO instruments or that challenge accepted doctrine on 
what actually constitutes SSc-RP (Figure 2) [37]. RP is usually defined as episodic digital 
vasoconstriction in response to cold exposure or emotional stress. This definition implies the 
absence of digital microvascular compromise in between “attacks”. This paradigm is at the heart of 
the diary-based approaches to assessing RP severity but may not entirely capture the experience of 
patients with SSc, for whom the obliterative microangiopathy results in more persistent digital 
ischaemia. For example, the Raynaud’s Severity Score diary (predecessor of the RCS diary) defined a 
Raynaud’s attack as an episode of pallor followed by cyanosis with or without associated pain [21]. 
Our recent qualitative research suggests the term RP represents a more nebulous concept for 
patients with SSc; whose physical symptoms comprise discrete attacks occurring on a background of 
more persistent pain, numbness and digital discolouration secondary to more sustained digital 
ischaemia [37]. Some patients report difficulty knowing when they are experiencing a RP “attack” 
and others report their fingers feeling constantly cold, numb, discoloured and painful (all symptoms 
they associate with their “Raynaud’s”) [37]. The RCS diary does not capture a number of important 
experiences relevant to SSc-RP including emotional distress, body image dissatisfaction, relevant 
physical symptoms (such as feeling cold), adaptation and functional impairment (Figure 2) [18, 37]. 
This could have important implications for our interpretation of previous clinical trials. For example a 
double-blind randomised-controlled trial of bosentan therapy did not identify any improvement in 
the RCS diary parameters but did identify significant improvement in the Health Assessment 
Questionnaire Disability Index (HAQ-DI) in patients receiving active treatment [28]. Both “difficulty 
using hands” and “impact on daily life” were highlighted as important experiences of SSc-RP by 
patients with SSc and it is possible the HAQ-DI partially captures such experiences which are not 
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directly evaluated by the RCS diary [37]. Moreover, the RCS diary makes no account of the 
considerable efforts taken by patients to avoid or ameliorate the symptoms of RP [37, 38]. Unlike 
other rheumatic diseases characterised by disease flares, patients with SSc exert some control over 
their RP symptoms through cold avoidance. In the extreme, this can result in reticence to venture 
outdoors for fear of the effects of cold exposure which itself can become a cause of social isolation. 
These efforts can considerably under-estimate the true burden of RP captured using diary-based 
instruments such as the RCS diary and may account for its relative poor performance in RP clinical 
trials (particularly those in which frequency of RP is the designated primary endpoint). Consistent 
with many early PRO instruments, there was no patient involvement in the development of the RCS 
diary but work is currently ongoing to develop novel outcome measures for SSc-RP that are 
grounded in the patient experience of SSc-RP and conform to regulatory standards for PRO 
development [39, 40]. It is hoped these efforts will deliver a PRO that fully captures the patient 
experience of SSc-RP and allow a more detailed appraisal of the severity and impact of SSc-RP. This 
could support both drug development programs but also provide much needed comparative 
practice-based evidence for future clinical guidelines concerning existing treatments used in the 
management of SSc-RP. 
Non-invasive microvascular imaging techniques provide an alternative approach to assessing 
therapeutic intervention in SSc-RP. Imaging protocols typically incorporate assessment of functional 
microvascular responses to provocation tests such as the local cold challenge [34, 35] or post-
occlusive reactive hyperaemia [41]. A number of clinical trials of SSc-RP have incorporated objective 
tests of cutaneous perfusion using thermal imaging [42] or laser-derived imaging modalities [43, 44, 
45, 46]. This approach is attractive as it can facilitate short-term proof-of-concept testing of novel 
therapeutic agents as a prelude to more costly clinical trials. Discordance between assessment of 
SSc-RP using PRO instruments and non-invasive microvascular imaging [34, 35] is a concern but it is 
hoped efforts to refine both methods will see convergent validity improve and encourage greater 
use of microvascular imaging as an accepted clinical trial endpoint.  
2.3 Digital ulcers 
DU disease is another major source of disease-related morbidity in SSc but, in contrast to RP, does 
not affect all patients with SSc. Large registry analyses suggest approximately 58% of patients with 
SSc will experience DU at some stage during the disease course [47]. Approximately one third of all 
SSc patients (particularly those with limited cutaneous SSc carrying anti-centromere or anti-Scl-70 
antibodies) will experience persistent or recurrent DU, of whom a third (approximately 10% of all 
patients with SSc) will experience complications of gangrene, require digital sympathectomy or 
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amputation as a result of their DU disease [47, 48]. A prospective study of a large SSc cohort 
estimated the incidence of new DU to be 17.4% over 18 months [49]. The incidence of finger 
amputation as a consequence of DUs was estimated to be 1.2 per 100 patient-years [49]. DUs are a 
common reason for hospitalisation in SSc and often necessitate the use of strong opioid analgesia 
[48, 49]. A history of SSc-DU is also a predictor of poorer outcome in SSc, including cardio-pulmonary 
involvement and survival [50].  SSc-DU are accompanied by reduced quality of life and impaired 
function, resulting in decreased work capacity and increased reliance on others for activities of daily 
living [51, 52, 53, 54]. Capillary loss at the nailfolds is strongly associated with DU disease [16, 55, 56, 
57, 58, 59] and can help predict future occurrence of DU [14, 15] suggesting irreversible digital 
ischaemia to be an important aetiological driver of DU disease - which itself may have important 
implications for both assessment and management.  
The management of SSc-DU concerns both healing of existing DU and prevention of new DU. The 
principle challenge in establishing efficacy for both objectives relates to defining what actually 
constitutes a DU and at what stage an existing DU can be considered healed. There is no universally 
agreed definition for DU and observational studies and clinical trials apply bespoke and sometimes 
diverse definitions of DU. For example, some studies specifically exclude calcinosis-related ulcers 
[54, 60, 61] whereas others do not [15, 62]. Some studies specify the site of the ulcer as being distal 
to the metacarpophalangeal joints [15], others distal to the proximal interphalangeal joints (PIPs) 
[60, 61, 62], whereas others place no restriction on the site of the cutaneous ulceration [54]. The 
appropriateness of allowing DUs on the volar aspect of the fingertips to be considered equal 
alongside DUs on the extensor aspects of the PIPs and distal interphalangeal joints, despite likely 
differences in aetiology, remains contentious and usually left to the discretion of investigators to 
define [61]. Hachulla et al. partially addressed this important issue by proposing three principal types 
of SSc-DU [63]. These comprise “(i) ulcers occurring at bony prominences, usually at 
metacarpophalangeal or interphalangeal joints of the fingers, promoted by microtraumatic events 
and by traction exerted on the sclerous skin when the fingers are flexed; (ii) ulcerations occurring at 
the level of subcutaneous calcifications where mechanical and inflammatory phenomena are also 
involved; and iii) ischemic DU that occur most frequently on distal areas of fingers, involving pulp or 
sometimes lateral edges.”[63]. Successful clinical trial programmes for DU management (resulting in 
marketing authorisation) have tended to focus on ischaemic DUs. For example, the RAPIDS-1 clinical 
trial evaluating the efficacy of bosentan therapy in the management of SSc-DU focussed on “ulcers 
at or distal to the proximal interphalangeal joint”, whilst the subsequent RAPIDS-2 trial focused on 
DUs that were “in a location judged compatible with a vascular aetiology, specified by protocol as 
volar surface of the digit distal to the proximal interphalangeal digital crease”. Case reports have 
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suggested traditional vasodilating approaches such as endothelin receptor antagonists might be less-
efficacious for non-ischaemic cutaneous ulcer management in SSc, and strongly supports sub-
classification of DUs for the purposes of SSc clinical trials  of SSc-DU  [64, 65]. 
The presence of overlying dry eschars (and whether to remove to seek evidence of ongoing 
denudation or re-epithelialisation) presents a particular problem when defining the presence and 
stage  of SSc-DU with various attempts made to define “active ulcer”, “inactive ulcers”, 
“indeterminate ulcers”, “healed ulcers” and “non-ulcers” [61, 66]. Even when consensus has been 
achieved as to what constitutes a DU and training in the application of agreed definitions 
undertaken, the inter-rater reliability remains low-moderate [61] and appears lower when 
photographs are used to determine ulcer grading, even when clinical contextual information is 
supplied [66, 67]. It should be noted that the strength of exercises to evaluate inter-rater agreement 
in DU classification is equally dependent on the diversity of digital ischaemic lesions chosen for 
grading as to the quality of the definitions applied.  Even when the issue of DU ulcer definition has 
been addressed, the overall burden of DU can differ greatly between patients.  Large registry 
analysis has led to the proposal of a novel categorisation approach to patients with SSc-DU disease 
that differentiates patients according to “no DU history” (33.2%), “episodic” (9.4%), “recurrent” 
(46.2%) and “chronic” (11.2%), in acknowledgment of the differing care needs of patients within 
these distinct sub-populations of patients [54].   Others have proposed similar classification 
approaches to “skin ulcers” in SSc [68]. These DU categorisation and classification approaches have 
important implications for clinical trial programmes for DU disease in SSc.  
Primary prevention of SSc-DU disease is challenging as DU often occur early in the course of SSc; 
with nearly half of patients with DU disease experiencing their first DU within 1 year of the first non-
RP symptom of SSc [63]. Conducting primary preventative studies would present a number of 
investigative challenges, which is a major frustration considering the potential “window of 
opportunity” and possibility of enhanced treatment efficacy at an earlier stage in the evolution of 
the obliterative micronagiopathy of SSc.  Unsurprisingly, cold exposure appears to be a risk factor for 
DU occurrence in SSc [69] which also has implications for clinical trial design with regards geographic 
location of recruiting centres and season of enrolment. The strongest predictor of future DU appears 
to be a prior history of DU [50]. This has resulted in clinical trials and prognostic studies examining 
future DU risk focussing on patients with a recent history of DU [15, 60, 62]. Several randomised 
controlled trials have examined secondary DU prevention and DU healing in SSc but differences 
between the evidence-base [70], expert consensus recommendations [30, 31], evidence-based 
recommendations [32] and regulatory marketing authorisation has resulted in geographic 
differences in management. For example, bosentan has marketing approval from the EMA for 
9 
Establishing treatment efficacy for cutaneous vascular manifestations of SSc 
secondary prevention of SSc-DU disease (following RAPIDS-1 and RAPIDS-2 clinical trials) but was not 
approved by the FDA for use in the US where bosentan use in SSc is almost exclusively limited to 
pulmonary vascular disease. Within the EU, the availability of bosentan for the management of DU 
disease may also be influenced by differing commissioning policies governing high-cost drug use 
within each member state. Registry data suggests significant geographic variation in practice when it 
comes to vasoactive therapy in SSc (encompassing SSc-RP and SSc-DU disease). For example, 
contemporary evaluations of intravenous iloprost use ranges from 1.3% of patients in Canada to 
21.1% of patients in Germany [71, 72]. 
Non-pharmacological approaches to DU management have not been the focus of controlled studies 
and the scleroderma community remaining evenly split as to whether interventions such as local DU 
debridement have no effect on DU healing, actively delay wound healing or actively encourage DU 
healing [61].  
Similar to SSc-RP, non-invasive microvascular imaging modalities such as laser Doppler and laser 
speckle contrast imaging are now being used to objectively assess treatment response in SSc-DU 
disease and could be promising outcomes in future DU clinical trials.  [73, 74] 
2.4 Telangiectasia 
Cutaneous telangiectasia are dilated post-capillary venules (without neovascularisation) that sit in 
the papillary or superficial reticular dermis [75, 76, 77]. There is endothelial thickening but no 
vasculitis or perivascular infiltrate [76]. They are a useful diagnostic marker of SSc and included in 
the classification of SSc [8]. Telangiectases are commonly found in exposed areas of skin of the 
hands and face andhave been reported to occur in approximately 80% of patients with SSc [78, 79].  
They are particularly prevalent in Caucasian patients carrying anti-centromere antibodies (hence 
their prominence in the CREST acronym) and the number of telangiectases is higher in current/ex-
smokers [78, 79, 80]. One study identified the presence of telangiectases in 76% of patients with SSc 
with a mean of 22.9 (SD 30.1) telangiectases per patient and with 7.3% being >1 mm in size [78]. It 
has been suggested that existing vasodilator therapies for SSc might contribute to worsening of 
facial telangiectases [81]. Whilst cutaneous telangiectases are themselves not life-threatening, their 
presence denotes advancement of the microangiopathy of SSc with strong associations with disease 
duration [80, 82], capillary drop out and neovascularisation at the nailfolds [11, 83], and pulmonary 
arterial hypertension [80, 82, 83, 84]. The strength of the association between telangiectases and DU 
remains less clear [79, 83, 85, 86]. Telangiectases can be disfiguring and a major cause of body image 
dissatisfaction, particularly when they occur in prominent areas such as the face (Figure 3).  
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Management of telangiectases includes concealment methods such as make-up camouflage and 
ablative treatments using injected sclerosing agents or thermocoagulation methods such as pulsed 
dye laser therapy. There is a high rate of recurrence following use of ablative methods, possibly 
relating to iatrogenic tissue injury exacerbating local tissue hypoxia.  Many observational  studies 
simply consider either the documented presence or absence of telangiectases [86] whereas other 
have undertaken more concerted efforts to grade the severity of telangiectasia formation through 
counting telangiectasia and applying a nominal scoring system across 11 body sites (the 
telangiectasia score) [80]. Modified versions of this method have been applied to grade 
telangiectases as absent, mild-to-moderate (1-10 on hands or face)  or diffuse (>10 on hands or face) 
[83]. Others have sub-classified telangiectases according to their clinical or dermatoscopic 
appearance resulting in the application of terms such as “spot” [11, 87], “reticular” [11, 87], “pseudo 
tumoral” (>5mm in diameter) [83] and “matt” telangiectases [88]. The semi-quantifiable methods 
applied so far include body areas not commonly affected (or complained about) and do not allow for 
the significant variation in severity that could exist at a single site (where 2 telangiectases vs. 9 
telangiectases attract the same score). For example, a patient could have 9 telangiectases on the 
face resulting in significant body image dissatisfaction and yet only score 1 using the method 
proposed by Shah et al, resulting in a potential “floor effect” [80].  
Clinical trials of interventions for telangiectases  have generally assessed treatment efficacy by 
comparing photographs before and after therapy using  ordinal scales, ranging from much worse, 
worse, unchanged, improved and much improved) [89, 90], or by examining lesion size and 
evaluation of lesion clearance [76]. Non-invasive imaging methods have been used to support clinical 
assessments including laser Doppler and dermatoscopy [89, 90]. The patient-reported Adapted 
Satisfaction With Appearance Scale (A-SWAP) has been shown to improve following laser therapy 
whereas the Hospital Anxiety and Depression Scale did not improve following laser treatment [90]. 
There are a number of barriers that need to be overcome to improve the management of 
telangiectases in SSc. Work is needed to establish what patients consider treatment success 
(reduction in size, reduction in number or eradication).  It is likely that sensitivity and reliability of 
PRO instruments could be improved through the development of instruments specific to SSc. 
Greater understanding of the aetiopathogenesis and natural history of telangiectases could one day 
be used to develop and promote primary preventative strategies.  
2.5 Critical digital ischaemia (CDI) 
CDI is a rare but serious complication of SSc. Approximately 10% of all patients with SSc, will 
experience complications of gangrene or require digital sympathectomy or amputation at some 
stage in their disease course [47, 48]. Digital amputation due to digital necrosis has been estimated 
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to occur in approximately 5% of patients with SSc [91]. A combination of the relatively rarity and 
severity of CDI presentation has resulted in the majority of published work in the subject arising 
from case reports or small case series. Published cases often report an aggravating factor such as 
concomitant anti-phospholipid syndrome (APLS) [92], overlap syndromes [93], concomitant drug use 
[94] or vasculitis [95]. In contrast to the aforementioned cutaneous vascular manifestations of SSc, 
peripheral macrovascular disease often contributes to the emergence of digital necrosis in SSc [91, 
96]. The eminence-based management of CDI typically involves admission to hospital for intensive 
vasodilator therapy (including intravenous prostanoids), aggressive management of contributory 
factors, surgical debridement and, depending on the clinical picture and co-morbidities, the 
consideration of potentially useful adjunct therapies including digital sympathectomy, anti-platelet 
therapy, short-term anticoagulation, statins and antibiotics [31] (Figure 4). Non-pharmacological 
treatments such as vacuum-assisted closure therapy have been applied to promote wound healing 
and save limbs [96] (Figure 5).  
There are a number of challenges in the assessment and management of CDI in SSc. Similar to SSc-
DU disease, there is marked variation in classification definitions that have influenced the reported 
prevalence of CDI in SSc [47, 49, 54, 63, 97, 98] (Table 2). A consensus definition of CDI (perhaps 
including a grading structure to allow categorisation) would allow more definitive assessment of the 
true burden of CDI to be undertaken within disease registries. The evidence-base for managing CDI is 
scant and controlled clinical trials are inconceivable given the rarity and severity of presentation. 
Nonetheless, large multicentre collaborative studies provide an opportunity to establish risk factors 
and compare outcomes to provide much needed “practice-based evidence” upon which future 
clinical guidelines may be based. A better understanding of the risk factors of CDI could be used to 
devise primary preventative strategies e.g. anticoagulation in patients with APLS antibodies or 
prophylactic angioplasty in patients with sub-clinical peripheral vascular disease.  
3.0 Conclusions 
Cutaneous vascular manifestations of SSc are a major cause of disease-related morbidity and have 
historically received less attention than potentially life-threatening internal organ complications of 
SSc but there is cause for optimism. Better knowledge of the pathogenesis of cutaneous 
vasculopathy, a deeper understanding of the patient experience of cutaneous vascular disease, 
efforts to improve outcome measures and a broader repertoire of therapeutic options offer 
encouragement that greater attention on cutaneous vascular disease shall deliver better outcomes 
and improved quality of life for patients with SSc. 
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4.0 Expert commentary 
Cutaneous vascular manifestations of SSc are a major cause of disease-related morbidity in terms of 
pain, loss of function, work absenteeism, reduced social participation and body image 
dissatisfaction. The non-life-threatening nature of these important disease manifestations can result 
in complacency amongst clinicians in terms of primary preventative intervention and management 
of existing cutaneous vascular disease. The physical and psychosocial burden of cutaneous vascular 
manifestations of SSc should not be underestimated. The last 15 years has witnessed considerable 
industry interest with well-designed large multicentre clinical trials conducted in the management of 
SSc-RP and SSc-DU disease. Establishing treatment efficacy has presented a challenge and risks 
waning industry engagement in this field. Advances in the management of internal organ disease in 
SSc has resulted in longer life-expectancy and greater attention is now being focussed on non-life 
threatening manifestations of SSc such as cutaneous vascular disease. This provides cause for 
optimism. Better knowledge of the pathogenesis of cutaneous vasculopathy, a deeper 
understanding of the patient experience of cutaneous vascular disease, efforts to improve outcome 
measures and a broader repertoire of therapeutic options offer encouragement that greater 
attention shall now focus on cutaneous vascular disease, the management of which may have far-
reaching unintended favourable effects within other organ systems in SSc. 
5.0 Five-year review 
The next five years is likely to deliver major advances in the management of cutaneous vascular 
disease in SSc. A number of drivers have resulted in the SSc academic community taking greater 
interest in this hitherto relatively neglected area of SSc therapeutics. These include greater 
recognition of the considerable morbidity associated with cutaneous vascular disease, the power of 
patient advocacy groups directing research funding strategies, improved understanding in disease 
pathogenesis and a broader repertoire of therapeutic options and candidate therapeutic targets.  
Current collaborative initiatives are expected to deliver robust definitions and clinical trial outcomes 
for each of the four major cutaneous vascular manifestations of SSc over the next 5 years. The expiry 
of drug patents shall see a fall in the price of high-cost drugs that will support more flexible 
reimbursement schemes that lead to repositioning of existing treatments within accepted clinical 
practice guidelines. This process has already begun and there is now considerably greater use of 
phosphodiesterase inhibitors for cutaneous vascular manifestations of SSc than could have been 
imagined 5 years ago. The emergence of practice-based evidence for the management of cutaneous 
vascular manifestations of SSc will support an appraisal of the comparative efficacy of different 
classes of vasodilator therapy, potentially supporting more personalised approaches to intervention 
and a new focus on primary preventative strategies.  
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6.0 Key issues 
 
 Cutaneous vascular manifestations of systemic sclerosis comprise Raynaud’s phenomenon, 
digital ulceration, telangiectasia formation and critical digital ischaemia; each of which are a 
major cause of systemic sclerosis disease-related morbidity 
 Despite a large number of promising vasodilator treatments available for use, only a limited 
number been issued marketing approval by regulatory agencies for managing cutaneous 
vascular manifestations of systemic sclerosis. 
 Demonstrating treatment efficacy for cutaneous vascular manifestations of SSc is 
challenging and there have been several disappointing clinical trials of promising vasoactive 
treatments in SSc. There is a risk of waning industry engagement in drug development 
programmes in this field. 
 Disparity between consensus best-practice guidelines, evidence-based recommendations 
and marketing authorisation has resulted in geographic variation in clinical practice 
concerning management of cutaneous vascular manifestations of SSc.  
 The development of robust and reliable clinical trial endpoints will be an important step in 
the delivery of successful drug development programmes for cutaneous vascular 
manifestations of systemic sclerosis  
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Figure 1. Clinical and nailfold capillaroscopy findings in a lady presenting with recent-onset 
systemic sclerosis.  
A) In addition to recent-onset bi-phasic Raynaud’s symptoms there was evidence of active ischaemic 
digital ulceration of left 4th digit and a solitary telangiectasia overlying the dorsal aspect of the left 3rd 
proximal interphalangeal joint. There was no overt skin thickening. B) Despite the short disease 
duration nailfold capillaroscopy revealed typical structural abnormalities of SSc with giant capillaries, 
microhaemorrhages, capillary drop out and disorganised neoangiogenesis. Anti-centromere 
autoantibodies were identified on serological investigation.  
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Table 1. Subtle differences in the design and item wording of SSc-RP PRO instruments (such as 
inclusion of painful sores) could influence outcomes when assessing SSc-RP severity 
 
Adapted from [18]  
Name Study Item metric Recall 
Period 
Score Item Wording 
Raynaud’s 
Severity 
Scale  
Wigley 
et al. 
1994 
[21] 
11-point 
numeric 
rating scale 
(0-10) 
1 day Mean 
daily 
score 
over 3-
week 
period 
Patients were asked to consider in their 
Raynaud severity score the number and 
duration of attacks; symptoms, such as 
numbness, burning, and pain and 
tingling; hand disability; and influence of 
cold on daily activity. An attack was 
defined as an episode of pallor followed 
by cyanosis with or without associated 
pain. 
Raynaud’s 
Condition 
Score 
Black et 
al. 1998 
[23]  
11-point 
numeric 
rating scale 
(0-10); 0 
None – 10 
very severe 
1 day Mean 
daily 
score 
over 2-
week 
period  
Please rate the difficulty you had today 
with your Raynaud’s condition. Please 
consider the following when choosing 
your score: The number of Raynaud’s 
attacks; the duration of the attacks; 
whether you had, for example, 
numbness, burning and tingling, and the 
effect cold had on your ability to use your 
hands and to perform other activities. 
Raynaud’s 
Condition 
Score 
Wigley 
et al. 
1998 
[22] 
11-point 
numeric 
rating scale 
(0-10); 0 No 
difficulty -10 
Extreme 
difficulty 
1 day Mean 
daily 
score 
over 2-
week 
period 
The Raynaud’s Condition Score is your 
rating of how much difficulty you had 
with your Raynaud’s TODAY. Consider 
how many attacks you had and how long 
they lasted. Consider how much pain, 
numbness, or other symptoms the 
Raynaud’s caused in your fingers 
(including painful sores) and how much 
the Raynaud’s ALONE affected the use of 
your hands today.  
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Figure 2. A conceptual map of the inter-related themes comprising the patient experience of SSc-
RP. 
 
 
  
Reproduced with permission from [37] 
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Figure 3. Widespread mat telangiectasia on the face of a patient with diffuse cutaneous systemic 
sclerosis (anti-U3-RNP antibody positive).  
The patient reported high scores for items within the social discomfort and dissatisfaction with 
appearance subscales of the Brief Satisfaction With Appearance (Brief-SWAP) instrument. 
  
26 
Establishing treatment efficacy for cutaneous vascular manifestations of SSc 
Table 2. Impact on reported prevalence of differing definitions applied to severe/critical digital 
ischaemia in SSc 
DU, digital ulcer 
Author, Year Description Definition  Prevalence of 
CDI 
Prevalence 
of Digital 
Necrosis 
/Gangrene 
Amputation 
Herrick 1994 
[98] 
Severe 
Ischaemia 
“amputation, surgical 
debridement or admission 
for intravenous vasodilator 
therapy” 
31/68 (45.6%) 
 
13/68 (19%) 
Harrison 
2002 [97] 
Digital 
ischaemia 
“if 1 or more of the 
following were reported: 
hospital admission for 
intravenous (IV) 
administration of 
vasodilator therapy (either 
prostacyclin or iloprost), 
surgical debridement of ≥1 
digits or surgical 
amputation of ≥1 digits” 
46/101 (46%) 
prostacyclin 
17/101 (17%) 
Surgical 
debridement  
 
15/101 
(15%) 
Haschulla 
2007 [63] 
Critical 
finger 
ischemia 
“Cold and cyanotic finger” 30/101 (30%) 8/101 (8%) 3/101 (3%) 
In patients with history of ischaemic DU: 
30/44 (68%) 8/44 (18%) 3/44 (7%) 
Nihtyanova 
2008 [49] 
Critical 
Digital 
ischaemia 
“a sustained reduction in 
digital perfusion with 
impaired tissue viability” 
19/1168 (1.6) 
(over 18-
months) 
16/1168 
(1.4)  
(over 18/12) 
11/1168 
(0.9)  
(over 18/12) 
Steen 2009 
[47] 
 “Severe” 
digital 
vasculo-
pathy 
“complicated by gangrene, 
or requiring digital 
sympathectomy or 
amputation” 
197/2080 
(9.5%) 
11% of patients have 
undergone amputation or 
experienced gangrene 
(absolute figures not 
provided)  
Matucci-
Cerinic 
2016 [54] 
Critical 
Digital 
Ischaemia 
“This is not a Raynaud’s 
phenomenon. It is a 
prolonged severe 
persistent reduction in 
digital tissue perfusion 
without re-warming” 
379/828 (45.8) 306/1352 
(22.6) 
104/1164 
(8.9) 
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Figure 4. Critical digital ischaemia in systemic sclerosis.  
A lady with systemic sclerosis characterised by Raynaud’s phenomenon, Puffy fingers, abnormal 
nailfold capillaroscopy and positive anti-centromere antibodies developed critical digital ischaemia 4 
years after presentation. A positive lupus anticoagulant was identified during investigation. 
Management consisted of approximately 1 month of near-continuous intravenous prostanoids, 
analgesia, low-dose steroids, calcium channel blocker, sildenafil, warfarin and bosentan. Surgical 
debridement of the necrotic digits was undertaken once the digital ischaemic was stabilised. A) The 
appearances of the digits shortly after presentation; B) The appearances of the hands post-
operatively. 
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Figure 5. Vacuum-assisted closure (VAC) therapy in the management of critical digital ischaemia in 
SSc.  
Serial photographs of the right foot of a 91 year old lady with SSc (positive anti-centromere 
antibodies who developed critical digital ischamia: (A) shortly after presentation, (B) post-
amputation before commencement of VAC therapy; (C) after completion of 43 days of treatment 
with VAC therapy; and (D) at 4 months post-VAC therapy. 
 
Reproduced with permission from [96] 
 
